| Autor: |
Stenach, Nina, Cottrell, Earl D., Fisher, Carol A., Kappa, Jeffrey R., Addonizio, V. Paul, Stenach, Nina, Cottrell, Earl D., Fisher, Carol A., Kappa, Jeffrey R., Addonizio, V. Paul |
| Zdroj: |
Journal of Extra-Corporeal Technology; September 1987, Vol. 19 Issue: 3 p258-264, 7p |
| Abstrakt: |
(J. Extra-Corpor. Technol.19[3] p. 258-264 Fall 1987, 23 ref.) Contact between blood and synthetic/air interfaces during extracorporeal circulation (ECC) results in adverse platelet alterations. We tested the efficacy of a new reversible potent prostacyclin analogue, iloprost (ZK 36374), in preventing these untoward conseguences in fifteen mongrel dogs undergoing extracorporeal circulation using either a membrane or bubble oxygenator. In treated groups, infusion of iloprost was incrementally increased to 150 ng/kg/min at least 15 minutes prior to incision. Equal infusion volumes of saline were administered to the control group. Platelet counts in control dogs (n = 6, membrane/control) decreased to 57 ± 10% (mean ± standard error of the mean) of initial levels by 30 minutes of ECC; in contrast, dogs infused with iloprost demonstrated consistently stable platelet counts despite perfusion with either membrane (1 07 ± 1 0%, n = 6) or bubble (81 ± 13%, n = 3) oxygenators. At 30 minutes of ECC, the iloprost infusion was discontinued. Although the platelet counts in the membrane iloprost-treated group continued to remain stable (99 ± 7%), platelet counts in the bubble iloprost-treated group droppped precipitously to 49 ± 1 0% within 60 minutesof discontinuance of infusion. Furthermore, by 90 minutes of ECC, platelets continued to demonstrate reduced sensitivity to ADP as measured by percent light transmission in both control (53 ± 15%) and bubble iloprost-treated (20 ± 16%) groups. In contrast, the membrane iloprost-treated group regained normal reactivity (80 ± 15%). We conclude that iloprost effectively prevents adverse platelet alterations during ECC. Furthermore, its salutary effects in membrane oxygenator systems persist long after platelet functional inhibition is reversed. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
